ReviewInternational journal of molecular sciences2021
Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Comparative Dosimetry of Single and HybridDiseases (Basel, Switzerland) · 2026Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [European journal of nuclear medicine and molecular imaging · 2024Observational
- DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [International journal of molecular sciences · 2024Article
- SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Impact of different models based on blood samples and images for bone marrow dosimetry afterEJNMMI physics · 2024Article
- Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.Trends in cancer · 2023Review
- PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The preclinical study ofAnnals of nuclear medicine · 2023Article
- Recombinant αBiomolecules · 2023Article
- A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [European journal of nuclear medicine and molecular imaging · 2023Article
- Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90.EJNMMI physics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of dosimetry and studies in peptide receptor radionuclide therapy (PRRT) over the past two decades are reviewed. Differences in kidney and bone marrow toxicity reported between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.